A Study Evaluating the Safety and Pharmacokinetics of QTORIN Rapamycin 3.9% Anhydrous Gel in the Treatment of Adults With Pachyonychia Congenita
Recruiting now · Phase 3
Conditions studied: Pachyonychia Congenita
In brief
PALV-08 is a multicenter, open-label treatment (OLT) study enrolling adults with Pachyonychia Congenita (PC) with genotyped keratin mutations KRT6A, KRT6B, KRT6C or KRT16 who were previously enrolled in the PALV-05 (VAPAUS) trial. The purpose of this OLT study is to investigate the safety of long term exposure and pharmacokinetics (PK) of QTORIN rapamycin 3.9% anhydrous gel or "PTX-022".
Key facts
- Study ID
- NCT05643872
- Run by
- Palvella Therapeutics, Inc.
- People needed
- 45
- Starts
- 2022-11-15
- Expected to finish
- 2023-11-01
- Last updated by the study team
- 2022-12-09
Who can join
Age: 16 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Minnesota Clinical Study Center — New Brighton, Minnesota, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.